Tofogliflozin hydrate etyltransferase Inhibitor II Allosteric inhibition enhances the efficacy

Allosteric inhibition enhances the efficacy of ABL kinase inhibitors to target unmutated BCR-ABL and BCR-ABL-T315I

1013-1021 (2019)

(2005) Nature

InChi: InChI=1S/C9H12N2O5/c12-4-5-6(13)7(14)8(16-5)11-3-1-2-10-9(11)15/h1-3

iNOS and COX-2 in A431 cells

Tofogliflozin hydrate etyltransferase Inhibitor II Allosteric inhibition enhances the efficacyTofogliflozin, also known as CSG 452, is a potent and high selective SGLT2 inhibitor under development the treatment of diabetes mellitus. Tofogliflozin improves glycaemic control and lowers body weight in patients with type 2 diabetes mellitus. Tofogliflozin dose dependently suppressed glucose entry into tubular cells. High glucose exposure (30 mM) for 4 and 24 h significantly increased oxidative stress generation in tubular cells, which were